XenoPort (NASDAQ: XNPT) is a biopharmaceutical company focused on harnessing the body’s intrinsic transport systems to improve the oral absorption, distribution, and pharmacokinetics of drugs. The company applies an integrated technology platform, consisting of transporter genomics, assay technology, and proprietary chemistries, to engineer drug molecules for active transport. XenoPort is currently applying its technology to off-patent drugs to provide new, patentable compounds with improved medicinal properties; and the company plans to work collaboratively with pharmaceutical companies to improve the pharmacokinetic properties of their proprietary drug candidates. XenoPort is taking a broad approach to drug transport, characterizing numerous transporter systems that have utility for drug delivery and developing the required chemistry strategies to engage these systems.
|02/04/04||Series C||37M||Elm Street Ventures, RWI Innogy, Viking Ventures,, SINTEF, Viking Ventures, SINTEF,, Naval Ravikant, Institutional Venture Partners’ Spark Capital, Harris and Harris Group, AAA Global Ventures, LLC, AT&T Media Holdings, Warner Bros., AutoDesk||Unknown|